In the present study, we excluded patients with oligodendroglioma, or those with IDH mutated- TERT promoter mutated, or both because oligodendroglioma is considered to show better prognosis than astrocytoma and is often accompanied by both IDH and TERT promoter mutations. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).